AVISE® Adalimumab and AVISE® Infliximab enable physicians to optimize therapy earlier by monitoring drug level activity with a reflex to neutralizing anti-drug antibodies.

This helps inform individualized therapeutic decisions based on data rather than empirical dose escalation. Continuous monitoring of new, existing and symptomatic patients with AVISE® Anti-TNF testing can help optimize dosing before further irreversible tissue damage & radiographic progression occur.

To learn more about the clinical utility of AVISE® Anti-TNF testing from your peers or read current scientific publications, please visit our Education & Resources library.